Nonresectional therapies for hepatocellular carcinoma

American Journal of Surgery

Volumn 173, Issue 4, 1997, Pages 358-365

  Liu, Chi Leung ^a   Fan, Sheung Tat ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL;

ARTICLE; ARTIFICIAL EMBOLISM; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CATHETER ABLATION; CRYOTHERAPY; LIVER CELL CARCINOMA; PRIORITY JOURNAL; TREATMENT PLANNING;

ANTINEOPLASTIC AGENTS, HORMONAL; CARCINOMA, HEPATOCELLULAR; COMBINED MODALITY THERAPY; CRYOTHERAPY; EMBOLIZATION, THERAPEUTIC; ETHANOL; HUMANS; IMMUNOTHERAPY; INJECTIONS, INTRALESIONAL; LIVER NEOPLASMS;

EID: 0030960950     PISSN: 00029610     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9610(96)00384-4     Document Type: Article

References (100)

1. Matsumata T, Kanematsu T, Shirabe K, et al. Decreased morbidity and mortality rates in surgical patients with hepatocellular carcinoma. Ann Surg. 1987;205:33-40.
2. Nagasue N, Kohno H, Chang YC, et al. Liver resection for hepatocellular carcinoma. Ann Surg. 1993;217:375-384.
3. The Liver Cancer Study Group of Japan. Primary liver cancer in Japan: clinicopathologic features and results of surgical treatment. Ann Surg. 1990;211:277-287.
4. Fan ST, Lai ECS, Lo CM, et al. Hospital mortality of major hepatectomy for hepatocellular carcinoma associated with cirrhosis. Arch Surg. 1995;130:198-203.
5. Lai ECS, Fan ST, Lo CM, et al. Hepatic resection for hepatocellular carcinoma. An audit of 343 patients. Ann Surg. 1995;221:291-298.
6. Okuda K, Fujimoto I, Hanai A, Urano Y. Changing incidence of hepatocellular carcinoma in Japan. Cancer Res. 1987;47:4967-4972.
7. The Liver Cancer Study Group of Japan. Primary liver cancer in Japan. Cancer. 1987;60:1400-1411.
8. Takayasu K, Muramatsu Y, Moriyama N, et al. Clinico-radiological evaluation of recurrence in the residual liver following hepatectomy in the residual liver following hepatectomy in 97 patients with hepatocellular carcinoma. Jpn J Gastroenterol. 1987;84:1424-1432.
9. Suenaga M, Nakao A, Harada A, et al. Hepatic resection for hepatocellular carcinoma. World J Surg. 1992;16:97-105.
10. Nonami T, Isshiki K, Katoh H, et al. The potential role of postoperative hepatic artery chemotherapy in patients with high risk hepatomas. Ann Surg. 1991;213:222-226.
11. Sitzman JV, Abrams R. Improved survival for hepatocellular cancer with combination surgery and multimodality treatment. Ann Surg. 1993;217:149-154.
12. Sugioka A, Tsuzuki T, Kanai T. Postresection prognosis of patients with hepatocellular carcinoma. Surgery. 1993;113:612-618.
13. Belghiti J, Panis Y, Farges Q, et al. Intrahepatic recurrence after resection of hepatocellular carcinoma complicating cirrhosis. Ann Surg. 1991;214:114-117.
14. Sugiura N, Takara K, Ohto M, et al. Treatment of small hepatocellular carcinoma by percutaneous injection of ethanol into tumor with real-time ultrasound monitoring. Acta Hepatol Jpn. 1983;24:920.
15. Ebara M, Kita K, Yoshikawa M, et al. Percutaneous ethanol injection for patients with small hepatocellular carcinoma. In: Tobe T, Kameda H, Okudaira, et al, eds. Primary Liver Cancer in Japan. Tokyo: Springer-Verlag; 1992;291-300.
16. Livraghi T, Bolondi L, Lazzaroni S, et al. Percutaneous ethanol injection in the treatment of hepatocellular carcinoma in cirrhosis. A study on 207 patients. Cancer. 1992;69:925-929.
17. Castells A, Bruix J, Bru C, et al. Treatment of small hepatocellular carcinoma in cirrhotic patients: a cohort study comparing surgical resection and percutaneous ethanol injection. Hepatology. 1993;18:1121-1126.
18. Isobe H, Sakai H, Imari Y, et al. Intratumour ethanol injection therapy for solitary minute hepatocellular carcinoma. A study of 37 patients. J Clin Gastroenterol 1994;18:122-126.
19. Ohnishi K, Ohyama N, Ito S, Fujiwara K. Small hepatocellular carcinoma: treatment with US-guided intratumoral injection of acetic acid. Radiology. 1994;193:747-752.
20. Cuschieri A, Crosthwaite G, Shimi S, et al. Hepatic cryotherapy for liver tumors. Development and clinical evaluation of a high-efficiency insulated multineedle probe system for open and laparoscopic use. Surg Endosc. 1995;9:483-489.
21. Charnley RM, Doran J, Morris DL. Cryotherapy for liver metastases: a new approach. Br J Surg. 1989;76:1040-1041.
22. Onik G, Rubinsky B, Zemel R, et al. Ultrasound-guided hepatic cryosurgery in the treatment of metastatic colon carcinoma. Preliminary results. Cancer. 1991;67:901-907.
23. Ravikumar TS, Kane R, Cady B, et al. A 5-year study of cryosurgery in the treatment of liver tumours. Arch Surg. 1991; 126:1520-1524.
24. Morris DL, Horton MD, Dilley AV, et al. Treatment of hepatic metastases by cryotherapy and regional cytotoxic perfusion. Gut. 1993;34:1156-1157.
25. Dalton RR, Eisenberg BL. Surgical management of recurrent liver tumors. Semin Oncol. 1993;20:493-505.
26. Zhou XD, Yu YQ, Tang ZY, et al. An 18-year study of cryosurgery in the treatment of primary liver cancer. Asian J Surg. 1992;15:43-47.
27. Kane RA. Ultrasound-guided hepatic cryosurgery for tumor ablation. Semin Intervent Radiol. 1993;10:132-142.
28. Olweny CLM, Toya T, Katongole-Mbidde E, et al. Treatment of hepatocellular carcinoma with adriamycin. Preliminary communication. Cancer. 1975;36:1250-1257.
29. 2) for hepatocellular carcinoma: clinical and pharmacokinetic results. Cancer Treat Rep. 1984;68:487-491.
30. Lai CL, Wu PC, Chan GCB, et al. Doxorubicin versus no antitumour therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer. 1988;62:479-483.
31. Hochster HS, Green MD, Speyer J, et al. 4'Epirubicin (Epirubicin): activity in hepatocellular carcinoma. J Clin Oncol. 1985;3:1535-1340.
32. Shiu W, Leung N, Li M, et al. The efficacy of high-dose 4'Epidoxorubicin in hepatocellular carcinoma. Jpn J Clin Oncol. 1988;18:235-237.
33. Davis RB, Van Echo DA, Leone LA, et al. Phase II trial of mitoxantrone in advanced primary liver cancer: a Cancer Leukemia Group B Study. Cancer Treat Rep. 1986;70:1125-1126.
34. Falkson G, Ryan LM, Johnson LA, et al. A random phase II study of mitoxantrone and cisplatin in patients with hepatocellular carcinoma. An ECOG study. Cancer. 1987;60:2141-2145.
35. Ravry MJR, Omura GA, Bartolucii AA, et al. Phase II evaluation of cisplatin in advanced hepatocellular carcinoma and cholangiocarcinoma: a Southern Cancer Study Group Trial. Cancer Treat Rep. 1986;70:311-312.
36. Cavalli F, Rozencweig M, Renard J, et al. Phase II study of oral VP-16-213 in hepatocellular carcinoma. Eur J Cancer Clin Oncol. 1981;17:1079-1082.
37. Shiu W, Mok SD, Leung N, et al. Phase 2 study of high dose etoposide (VP16-213) in hepatocellular carcinoma. Jpn J Clin Oncol. 1987;17:113-115.
38. Ohya T, Kikuchi S, Kato K, et al. Clinical studies of chemotherapy for primary hepatocellular carcinoma. Jpn J Cancer Chemother. 1982;9:1623-1627.
39. Falkson G, Coetzer B. Chemotherapy of primary liver cancer. In: Okuda K, Ishak KJ, eds. Neoplasms of Liver. Tokyo: Springer-Verlag; 1987:331-326.
40. Falkson G, MacIntyre JM, Moertel CG, et al. Primary liver cancer: an Eastern Cooperative Oncology Group Trial. Cancer. 1984;54:970-977.
41. Breedis C, Young G. The blood supply of neoplasm in the liver. Am J Pathol. 1954;30:969-977.
42. Takayasu K, Shima Y, Muramatsu Y, et al. Hepatocellular carcinoma: treatment with intraarterial iodized oil with and without chemotherapeutic agents. Radiology. 1987;162:345-351.
43. Sasaki Y, Imaoka S, Kasugai H, et al. A new approach to chemoembolization therapy for hepatoma using ethiodized oil, cisplatin and gelatin sponge. Cancer. 1987;60:1194-1203.
44. Shimamura Y, Gunven P, Takenaka Y, et al. Combined peripheral and central chemoembolization of liver tumors. Experience with Lipiodol-doxorubicin and gelatin sponge (L-TEA). Cancer. 1988;61:238-242.
45. Yamada R, Kishi K, Terada M, et al. Transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma. In: Tobe T, Kameda H, Okudaira, et al, eds. Primary Liver Cancer in Japan. Tokyo: Springer-Verlag; 1992:259-271.
46. Nakamura H, Hashimoto T, Oi H, Sawada S. Transcatheter oily chemoembolization of hepatocellular carcinoma. Radiology. 1989;170:783-786.
47. Hsieh MY, Chang WY, Wang LY, et al. Treatment of hepatocellular carcinoma by transcatheter arterial chemoembolization and analysis of prognostic factors. Cancer Chemother Pharmacol. 1992;31(suppl):S82-85.
48. Yang CF, Ho YJ. Transcatheter arterial chemoembolization for hepatocellular carcinoma. Cancer Chemother Pharmacol. 1992;31(suppl):S86-88.
49. Yamamoto K, Masuzawa M, Kato M, et al. Analysis of prognostic factors in patients with hepatocellular carcinoma treated by transcatheter arterial embolization. Cancer Chemother Pharmacol. 1992;31(suppl):S77-81.
50. Ngan H, Lai CL, Fan ST, et al. Treatment of inoperable hepatocellular carcinoma by transcatheter arterial chemoembolization using an emulsion of cisplatin in iodized oil and gelfoam. Clin Radiol. 1993;47:315-320.
51. Stuart K, Stokes K, Jenkins R, et al. Treatment of hepatocellular carcinoma using doxorubicin/ethiodized oil/gelatin powder chemoembolization. Cancer. 1993;72:3202-3209.
52. Bronowicki JP, Vetter D, Dumas F, et al. Transcatheter oily chemoembolization for hepatocellular carcinoma. A 4-year study of 127 French patients. Cancer. 1994;74:16-24.
53. Modazzi L, Bottelli R, Brambilla G, et al. Transarterial oily chemoembolization for the treatment of hepatocellular carcinoma: a multivariate analysis of prognostic factors. Hepatology. 1994;19:1115-1123.
54. Pelletier G, Roche A, Ink O, et al. A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol. 1990;11:181-184.
55. Kasugai H, Kojima J, Tatsuta M, et al. Treatment of hepatocellular carcinoma by transcatheter arterial embolization combined with intraarterial infusion of a mixture of cisplatin and ethiodized oil. Gastroenterology. 1989;97:965-971.
56. Groupe d'etude et de traitement du carcinome hepatocellulaire. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. NEJM. 1995;332:1256-1261.
57. Takayasu K, Suzuki M, Vesaka K, et al. Hepatic artery embolization for inoperable hepatocellular carcinoma: prognosis and risk factors. Cancer Chemother Pharmacol. 1989;23 (suppl):123-125.
58. Ikeda K, Kumada H, Saitoh S, et al. Effect of repeated transcatheter arterial embolization on survival time of patients with hepatocellular carcinoma. Cancer. 1991;68:2150-2154.
59. Yu YQ, Xu DB, Zhou XD, et al. Experience with liver resection after hepatic arterial chemoembolization for hepatocellular carcinoma. Cancer. 1993;71:62-65.
60. Bismuth H, Morino M, Sherlock D, et al. Primary treatment of hepatocellular carcinoma by arterial chemoembolization. Am J Surg. 1992;163:387-94.
61. Shimamura Y, Ishii M, Ono M, et al. Arterial infusional therapy: lipiodol-cytostatics with and without embolization. In: Tobe T, Kameda H, Okudaira, et al, eds. Primary Liver Cancer in Japan. Tokyo: Springer-Verlag; 1992:273-281.
62. Jeng KS, Ching HJ. The role of surgery in the management for unusual complications of transcatheter arterial embolization for hepatocellular carcinoma. World J Surg. 1988;12:362-368.
63. Aoki K, Okazaki N, Okada S, et al. Radiotherapy for hepatocellular carcinoma: Clinicopathological study of seven autopsy cases. Hepatogastroenterology. 1994;41:427-431.
64. Matsuzaki Y, Osuga T, Saito Y, et al. A new, effective, and safe therapeutic option using proton itradiation for hepatocellular carcinoma. Gastroenterology. 1994;106:1032-1041.
65. Raoul JI, Bretagne JF, Caucanas JP, et al. Internal radiotherapy for hepatocellular carcinoma. Results of a French multicentre phase II trial of transarterial injection of iodine-131-labeled Lipiodol. Cancer. 1992;69:346-352.
66. Leung WT, Lau WY, Ho S, et al. Selective internal radiation therapy with intra-arterial iodine-131-Lipiodol in inoperable hepatocellular carcinoma. J Nucl Med. 1994;35:1313-1318.
67. Houle S, Yip TK, Shepherd FA, et al. Hepatocellular carcinoma: pilot trial of treatment with Y-90 microspheres. Radiology. 1989;172:857-860.
68. Shepherd FA, Rotstein LE, Houle S, et al. A phase I dose escalation trial of yttrium-90 microsphcrcs in the treatment of primary hepatocellular carcinoma. Cancer. 1992;70:2250-2254.
69. Lau WY, Leung WT, Ho S, et al. Treatment of inoperable hepatocellular carcinoma with intrahepatic arterial yttrium-90 microspheres: a phase I and II study. Br J Cancer. 1994;70:994-999.
70. Gupta S, Korula J. Failure of ketoconazole as anti-androgen therapy in nonresectable primary hepatocellular carcinoma. J Clin Gastroenterol. 1988;10:651-654.
71. Forbes A, Wilkinson ML, Iqbal MJ, et al. Response to cyproterone acetate treatment in primary hepatocellular carcinoma is related to fall in free 5α-dihydrotestosterone. Eur J Cancer Clin Oncol. 1987;23:1659-1664.
72. Friedman MA, Demanes DJ, Hoffmann PG. Hepatomas: hormone receptors and therapy. Am J Med. 1982;73:362-366.
73. Engstrom PF, Levin B, Moertel CG, Chutt A. A phase II trial of tamoxifen in hepatocellular carcinoma. Cancer. 1990;65:2641-2643.
74. Farinati F, De-Maria N, Fornasiero A, et al. Prospective controlled trial with antiestrogen drug tamoxifen in patients with unresectable HCC. Dig Dis Sci. 1992;37:659-662.
75. Martinez Cerezo FJ, Tomas A, Donoso L, et al. Controlled trial of tamoxifen in patients with advanced hepatocellular carcinoma. J Hepatol. 1994;20:702-6.
76. Hirofuji H, Kakumu S, Fuji A, et al. Natural killer and activated killer activities in chronic liver diseases and hepatocellular carcinoma: evidence for a decreased lymphokine-induced activity of effector cells. Clin Exp lmmunol. 1987;68:348-356.
77. Saibara T, Ohnishi S, Sakaeda H, et al. Defective function of lymphokine-activated killer cells and natural killer cells in patients with hepatocellular carcinoma. Hepatology. 1989;9:471-476.
78. Isaacs A, Lindermann J. Virus interference. The interferon. Proc R Soc Land [Biol]. 1957;147:259-267.
79. Sachs E, Di Bisceglie AM, Dusheiko GM, et al. Treatment of hepatocellular carcinoma with recombinant leukocyte interferon: A pilot study. Br J Cancer. 1985;52:105-109.
80. Yoshida T, Okazaki N, Toshino M, et al. Phase II trial of high dose recombinant gamma-interferon in advanced hepatocellular carcinoma. Eur J Cancer. 1990;26:545-546.
81. Kardinal CG, Moertel CG, Wieand HS, et al. Combined doxorubicin and alpha-interferon therapy of advanced hepatocellular carcinoma. Cancer. 1993;71:2187-2190.
82. Colleoni M, Buzzoni R, Bajetta E, et al. A phase II study of mitoxantrone combined with beta-interferon in unresectable hepatocellular carcinoma. Cancer. 1993;72:3196-3201.
83. Feun LG, Savaraj N, Hung S, et al. A phase II trial of recombinant leukocyte interferon plus doxorubicin in patients with hepatocellular carcinoma. Am J Clin Oncol. 1994;17:393-395.
84. Lai CL, Wu PC, Lok AS, et al. Recombinant alpha 2 interferon is superior to doxorubicin for inoperable hepatocellular carcinoma: a prospective randomised trial. Br J Cancer. 1989;60:928-933.
85. Lai CL, Lau JY, Wu PC, et al. Recombinant interferon-alpha in inoperable hepatocellular carcinoma: a randomized controlled trial. Hepatology. 1993;17:389-394.
86. Huang GT, Yang PM, Sheu JC, et al. Intratumoral injection of OK-432 for the treatment of small hepatocellular carcinoma. Hepatogastroenterology. 1990;37:452-456.
87. Ohnishi S, Saibara T, Fujikawa M, et al. Adoptive immunotherapy with lymphokine-activated killer cells plus recombinant interleukin-2 in patients with unresecrable hepatocellular carcinoma. Hepatology. 1989;10:349-353.
88. Gandolfi L, Solmi L, Pizza GC, et al. Intratumoral echo-guided injection of interleukin-2 and lymphokine-activated killer cells in hepatocellular carcinoma. Hepatogastroenterology. 1989;36:352-356.
89. Tanaka K, Nakamura S, Numata K, et al. Hepatocellular carcinoma: treatment with percutaneous ethanol injection and transcatheter arterial embolization. Radiolagy. 1992;185:457-460.
90. Tatcishi H, Kinuta M, Furukawa J, et al. Follow-up study of combination treatment (TAE and PEIT) for unresectable hepatocellular carcinoma. Cancer Chemother Pharmacol. 1994;33(suppl):S119-123.
91. Koda M, Okamoto K, Miyoshi Y, et al. Combination therapy with transcatheter arterial embolization and percutaneous ethanol injection for advanced hepatocellular carcinoma. Hepatogastroenterology. 1994;41:25-29.
92. Lencioni R, Vignali C, Caramella D, et al. Transcatheter arterial embolization followed by percutaneous ethanol injection in the treatment of hepatocellular carcinoma. Cardiovasc Intervent Radiol. 1994;17:70-75.
93. Matsumata T, Kanematsu T, Tanaka K, Sugimachi K. Lack of intrahepatic recurrence of hepatocellular carcinoma by temporary portal venous embolization with starch microspheres. Surgery. 1989;105:188-191.
94. Fujio N, Sakai K, Kinoshita H, et al. Results of treatment of patients with hepatocellular carcinoma with severe cirrhosis of the liver. World J Surg. 1989;13:211-217.
95. Hwang TL, Chen MF, Lee TY, et al. Resection of hepatocellular carcinoma after transcatheter arterial embolization: reevaluation of the advantages and disadvantages of preoperative embolization. Arch Surg. 1987;122:756-759.
96. Nagasue N, Kohno H, Uchida M. Evaluation of preoperative transcatheter arterial embolization in the treatment of resectable primary liver cancer. Semin Surg Oncol. 1993;9:327-331.
97. Sitzmann JV, Abrams R. Improved survival for hepatocellular cancer with combination surgery and multimodality treatment. Ann Surg. 1993;217:149-154.
98. Tang ZY, Yu YQ, Zhou XD, et al. Treatment of unresectable primary liver cancer: with reference to cytoreduction and sequential resection. World J Surg. 1995;19:47-52.
99. London WT. Primary hepatocellular carcinoma - aetiology, pathogenesis and prevention. Hum Pathol. 1981;12:1085-1097.
100. Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepatocellular cancer and prognosis in relation to treatment: a study of 850 patients. Cancer. 1985;56:918-928.